CONFERENCE COVERAGE
Consortium of Multiple Sclerosis Centers
Annual Meeting
2023 COVERAGE
- Long-Term VidoCa Has Favorable Safety Profile in Relapsing-Remitting MS
- Tolebrutinib Remains Safe, Effective for Relapsing MS With Highly Active Disease
- Higher BMI Associated With MOGAD, Not NMO in Racially Diverse Population
- OCT-A Detects Greater Loss of Retinal Microvasculature in Patients With MS
- Inebilizumab Treatment for Patients With NMOSD May Not Up COVID-19 Risk
- Fatigue May Have Negative Effect on Cognition in Patients With MS
- Dimethyl Fumarate vs Fingolimod for MS: Which Has a Better Safety Profile?
- Dietary and Lifestyle Interventions Improve QOL Outcomes in Patients With RRMS
- Switch from Anti-CD20 to Fumarate May Be a Viable Treatment Option for MS
- Minimal Disease Activity Seen With Ocrelizumab for Early RRMS Over 4 Years
- Evobrutinib Recipients With RMS Mount Humoral Responses to COVID-19 Vaccines
- Latinx Patients With Multiple Sclerosis Present With Earlier Disease Onset
Latest Tweets
Follow
@NeuroAdvisor
Conference Coverage from
